Stoke Therapeutics is pioneering RNA-based therapies, with a lead candidate for Dravet Syndrome aiming for true disease modification, unlike current symptom-focused treatments. The company’s ...

Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study.

Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study.

Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome Myriam Alvarez Fri, Jun. 14, 2024 1 Comment ...

BEDFORD, Mass., June 17, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics in a deal that included an upfront payment of $165 ...

Stoke Therapeutics has a 52-week low of $5.35 and a 52-week high of $17.58. The stock has a market capitalization of $608.21 million, a price-to-earnings ratio of -5.30 and a beta of 1.09.

It’s mind-blowing what used to set them off." Faith had her first seizure at five months old and was diagnosed with Dravet Syndrome at 15 months after repeated emergency hospital visits.